These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16004595)

  • 1. Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target.
    Macphee C; Benson GM; Shi Y; Zalewski A
    Expert Opin Investig Drugs; 2005 Jun; 14(6):671-9. PubMed ID: 16004595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.
    Nambi V; Ballantyne CM
    Curr Atheroscler Rep; 2006 Sep; 8(5):374-81. PubMed ID: 16901407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein-associated phospholipase A2 as a target of therapy.
    Macphee CH; Nelson JJ; Zalewski A
    Curr Opin Lipidol; 2005 Aug; 16(4):442-6. PubMed ID: 15990594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis.
    Zalewski A; Macphee C; Nelson JJ
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):527-32. PubMed ID: 16503872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of lipoprotein-associated phospholipase A2 (Lp-PLA₂) in cardiovascular disease.
    Ikonomidis I; Michalakeas CA; Lekakis J; Parissis J; Anastasiou-Nana M
    Rev Recent Clin Trials; 2011 May; 6(2):108-13. PubMed ID: 21241231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target.
    Macphee CH; Nelson J; Zalewski A
    Curr Opin Pharmacol; 2006 Apr; 6(2):154-61. PubMed ID: 16495153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.
    Zalewski A; Macphee C
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):923-31. PubMed ID: 15731492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.
    Caslake MJ; Packard CJ
    Curr Opin Lipidol; 2003 Aug; 14(4):347-52. PubMed ID: 12865731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
    Corson MA; Jones PH; Davidson MH
    Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target.
    Ali M; Madjid M
    Future Cardiol; 2009 Mar; 5(2):159-73. PubMed ID: 19371190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence.
    Koenig W; Khuseyinova N
    Cardiovasc Drugs Ther; 2009 Feb; 23(1):85-92. PubMed ID: 18949547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque.
    Suckling KE; Macphee CH
    Expert Opin Ther Targets; 2002 Jun; 6(3):309-14. PubMed ID: 12223071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk?
    Lee JH; Engler MM
    Prog Cardiovasc Nurs; 2009 Dec; 24(4):181-9. PubMed ID: 20002343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.
    Gazi I; Lourida ES; Filippatos T; Tsimihodimos V; Elisaf M; Tselepis AD
    Clin Chem; 2005 Dec; 51(12):2264-73. PubMed ID: 16223884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men.
    Jang Y; Kim OY; Koh SJ; Chae JS; Ko YG; Kim JY; Cho H; Jeong TS; Lee WS; Ordovas JM; Lee JH
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3521-7. PubMed ID: 16787988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-associated phospholipase A2.
    McConnell JP; Hoefner DM
    Clin Lab Med; 2006 Sep; 26(3):679-97, vii. PubMed ID: 16938590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments with lipoprotein-associated phospholipase A2 inhibitors.
    Chauffe RJ; Wilensky RL; Mohler ER
    Curr Atheroscler Rep; 2010 Jan; 12(1):43-7. PubMed ID: 20425270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
    Ferri N; Corsini A
    G Ital Cardiol (Rome); 2014 Dec; 15(12):664-9. PubMed ID: 25533115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature.
    Madjid M; Ali M; Willerson JT
    Tex Heart Inst J; 2010; 37(1):25-39. PubMed ID: 20200624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.